COMPASS Pathways plc
CMPSHealthcare|Biotechnology|GB
$8.61
+0.80 (+10.24%)
DCF Value
$1.38
Tangible Book / Share
$1.02
Cash / Share
$3.20
About
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
Stock Price
+54.0%(1Y)
1M
-24.9%
3M
-36.4%
6M
-13.1%
YTD
+24.8%
1Y
+50.0%
3Y
+54.6%
5Y
-80.0%
Pipeline Summary
16 total trials0
Phase 1
12
Phase 2
4
Phase 3
0
Phase 4
Active: 2Recruiting: 2Completed: 9Withdrawn: 1Unknown: 2
Active Trials (4)
A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder
NCT05733546Major Depressive Disorder
Phase 2Active
Enrollment: 102 participants
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
NCT05711940Treatment Resistant Depression
Phase 3Active
Enrollment: 572 participants
Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
NCT07570654PTSD - Post Traumatic Stress Disorder
Phase 2Phase 3Recruiting
Enrollment: 300 participants
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
NCT06247839Major Depressive Disorder
Phase 3Recruiting
Enrollment: 20 participants
Key Facts
Market Cap$1.22B
Employees156 (-6% YoY)
CEOKabir Kumar Nath
IPO DateSep 18, 2020
Beta2.41
52-Week Range$4.88 – $15.87
Avg Volume3,364,741
ExchangeNASDAQ
Websitecompasspathways.com
Ownership
Float98.5%
Shares Outstanding141.5M
Recent Insider Trades
Nath KabirTAX W/H
Aug 3, 20265,962 shares @ $11.25
Karydas DaphneAWARD
May 27, 202621,110 shares @ $11.85
SANTINI GINOAWARD
May 27, 202630,158 shares @ $11.85
Gover Justin D.AWARD
May 27, 202621,110 shares @ $11.85
JONAS JEFFREY MAWARD
May 27, 202621,110 shares @ $11.85
Peers
Recent News
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 5, 2026 · businesswire.com
Compass Pathways Q3 Earnings Call Highlights
Nov 5, 2026 · defenseworld.net
Compass Pathways to Participate in Stifel 2026 Healthcare Conference on November 11th
Nov 4, 2026 · businesswire.com
Compass Pathways: 3 Key Takeaways for Long-Term Investors
Nov 3, 2026 · fool.com
COMPASS Pathways plc (CMPS) Q3 2026 Earnings Call Transcript
Nov 3, 2026 · seekingalpha.com
Data last updated: Nov 9, 2026, 04:02 AM